New Media Department             Yu Jie, Duan Yuqing              June 2, 2023

Pediatric psoriasis is a chronic, relapsing, immune, systemic skin disease that is often induced by a combination of genetic and environmental factors. Unlike adult psoriasis, the clinical manifestations of children's psoriasis are complex, and the treatment needs to pay more attention to safety. What's more difficult is that due to the particularity of children's medication, many adult treatments have not been approved for children, which makes the treatment of children's psoriasis face great challenges.

On May 25, 2023, ustekinumab was officially approved for the treatment of psoriasis in children and adolescents. The indications are children and adolescents aged 6 and over who have insufficient response to or cannot tolerate other systemic treatments or phototherapy ( Patients with moderate to severe plaque psoriasis weighing between 60kg and 100kg, the arrival of this news undoubtedly presents a special Children's Day "gift" to the majority of children with psoriasis and their families who are in dire straits.